Search Results
Search results for "Addex Therapeutics"
Results found for "Addex Therapeutics"
- Orion and Peptilogics are pursuing AI-driven drug discovery to explore new functional chemical ...
are pursuing AI-driven drug discovery to explore new functional chemical space and precision-engineer therapeutics
- Sosei Heptares and Kallyope Enter Collaboration to Identify and Validate Novel Gastrointestinal GPCR
leverage multiple sophisticated technologies that drive creation of new drug discovery programs in key therapeutic biology platform to identify potential GPCR targets and advance the development of new gastrointestinal therapeutics
- đź“° GPCR Weekly News
Therapeutic potential of allosteric modulators for the treatment of gastrointestinal motility disorders GPCRs in Oncology and Immunology Clinical, pathophysiologic, genetic and therapeutic progress in Primary Sosei Heptares and Neurocrine Biosciences won Out-Licensing Deal of the Year from Locust Walk Omass Therapeutics Use Disorders AbbVie recruits a GPCR team in Oxford, buying out a fledgling biotech for $255M+ Domain Therapeutics
- đź“° GPCR Weekly News, October 30 to November 4, 2023
, GPCRs, and more RGS proteins and cardiovascular Angiotensin II Signaling: Novel opportunities for therapeutic for Daridorexant (ACT-541468), a Dual Orexin Receptor Antagonist for the Treatment of Insomnia OMass Therapeutics Releases First Protein Structures in PDB, Advances Lupus Therapy Research Structure Therapeutics Receives
- Class B1 GPCR Dimerization: Unveiling Its Role in Receptor Function and Signaling
only enhances our understanding of class B1 GPCR biology but also opens new avenues for developing therapeutic Graaf, C., et al., Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic
- Assay Sensitivity: The Hidden Lever Driving GPCR Drug Discovery
It’s about revealing therapeutic liabilities before  they derail development. constitutive activity play in uncovering inverse agonists , and how can you exploit this phenomenon for novel therapeutic
- Discovery On Target, October 17-20, 2022, Boston, USA
and technologies, as well as target validation strategies for the discovery and development of novel therapeutic
- Opposite Effects of Src Family Kinases on YAP and ERK Activation in Pancreatic Cancer Cells...
As therapeutic options are limited, novel targets and agents for therapeutic intervention are urgently
- ShouTi Introduces Basecamp Bio as a Wholly Owned Subsidiary to Expand Pipeline and Partnerships
FRANCISCO & SHANGHAI- ShouTi Inc., a clinical-stage global biopharmaceutical company developing novel oral therapeutics
- đź“° GPCR Buzz: August 5-11, 2024 | Top Highlights from DrGPCR University!
From omics to epigenetics The impact of nanobodies on GPCR structural biology and their potential as therapeutic complexes with MolBoolean Screening GPR75 Modulators Using Medium-Throughput Reporter Gene Assay GPCR Therapeutics
- đź“° GPCR Weekly News, April 1 to 7, 2024
signaling in humoral immunity Industry News Neurosterix launches with $63M to Advance Allosteric Modulator Therapeutics Financial Resultsand Confirms Its 2024 Outlook Sosei Heptares officially changed their name to Nxera Domain Therapeutics
- đź“° GPCR Weekly News, February 20 to 26, 2023
Allosteric modulation of conserved motifs and helices in 5HT2BR: Advances drug discovery and therapeutic GPCRs in Cardiology, Endocrinology, and Taste α1-Adrenergic Receptors: Insights into Potential Therapeutic Industry News Josephine (Pina) Cardarelli from GPCR Therapeutics on Beyond Biotech Podcast Crinetics
- Terry’s Corner, Celtarys' Leap, and the $7B GPCR Horizon
– CXCR4 oligomer disruption boosts therapeutic response in lymphoid neoplasms Dr.
- Amgen to Acquire Chemocentryx for $4 Billion in Cash
and ChemoCentryx, Inc., (NASDAQ: CCXI), a biopharmaceutical company focused on orally administered therapeutics
- Novo Nordisk moves to strengthen obesity efforts
Novo Nordisk is strengthening its position in the obesity space through a collaboration with EraCal Therapeutics
- GPCR Pharmacology Insights That Prevent Real Drug Discovery Failures
PAMs assumed therapeutically viable without verifying whether they amplify affinity or efficacy. Lower-affinity alternatives may produce deeper, more therapeutically relevant coverage.
- Sosei Heptares Enters Antibody Discovery Agreement with Twist Bioscience to Discover and Develop ...
Sosei Heptares Enters Antibody Discovery Agreement with Twist Bioscience to Discover and Develop Novel Therapeutic high-quality synthetic DNA using its silicon platform, announced a strategic collaboration to discover therapeutic
- Extracellular signal-regulated kinases – a potential pathway for GPCR-targeted drug discovery
In summary, targeting GPCR-activated ERK pathways represents a promising strategy for developing new therapeutics ERK-dependent apoptosis as a potential therapeutic strategy for cancer. Cells, 10(10), 2509.
- Embark on a GPCR Adventure: Your Weekly Research Expedition! | Oct 21-27, 2024
20th World Congress of Basic and Clinical Pharmacology GPCR Jobs Scientist I Cell Biology - Tectonic Therapeutic
- Enzyme Inhibition Pharmacology: The Hidden Gatekeepers of GPCR Drug Discovery
These nuances define therapeutic potential and side-effect risk. Each mode reshapes both potency and therapeutic window.
- 🤯Mind-blowing GPCR Scoops! Discover the Latest Breakthroughs! ⦿ Nov 18 - 24, 2024
2025 Milestones Recursion and Exscientia have merged to enhance drug discovery GPCR Classes Pathios Therapeutics Basic and Clinical Pharmacology GPCR Jobs NEW Scientist - Biology Scientist I Cell Biology - Tectonic Therapeutic
- Applications of Cryo-EM in small molecule and biologics drug design
As a result, cryo-EM has begun to make major impacts in bringing critical therapeutics to market. In this review, we discuss recent instructive examples of impacts from cryo-EM in therapeutics design
- Molecular insights into psychedelic drug action
actions and suggest that these discoveries can facilitate new insights into their hallucinogenic and therapeutic
- Molecular targets of psychedelic-induced plasticity
toward exploring the relationship between the actual psychedelic effects and those manifestations of therapeutic
- InterAx Biotech AG and Boehringer Ingelheim take collaborate to unlock orphan targets leveraging ...
prediction of first-in-class small molecule agonists for a challenging orphan GPCR for a highly relevant therapeutic
- Targeting the M1 muscarinic receptor in neurodegenerative disease
the role of the muscarinic M1 receptor in cognitive and neurodegenerative disorders and the potential therapeutic
- From DNA day to GPCR genomics
GPCR-targeted drugs, and the exploration of GPCRs as key regulators of physiological processes and therapeutic analysis, have facilitated drug discovery and design targeting GPCRs, leading to the development of novel therapeutics
- Dr. Josephine (Pina) Cardarelli - Dr. GPCR Podcast
Pina Cardarelli, CSO of GPCR Therapeutics.
- Harnessing Deep Mutational Scanning for Enhanced Drug Discovery
development of more personalised therapies tailored to the genetic makeup of individual patients, enhancing therapeutic that can drive the early stages of target and lead identification, combat drug resistance, and refine therapeutic
- G protein-coupled receptor signaling: transducers and effectors
physiological functions and in a large number of Food and Drug Administration (FDA)-approved drugs as therapeutic










